<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818947</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OGB-IRE-2012/1</org_study_id>
    <nct_id>NCT01818947</nct_id>
  </id_info>
  <brief_title>Gefitinib Usage and Outcomes in Routine Treatment</brief_title>
  <official_title>A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand real world gefitinib usage patterns, patient
      characteristics and outcomes and to present these for a Caucasian population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes
      in routine treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of treatment duration, as a surrogate of Clinical Benefit (CB) in a 'Real World' population treated with gefitinib</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Overall Survival (OS) in a 'Real World' population treated with gefitinib</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Overall Survival (OS) in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Treatment duration in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of patients treated with gefitinib for all patients and stratified by whether gefitinib discontinued treatment before or after three months</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of treatment patterns in patients treated with gefitinib (prior chemo, treatment breaks, treatment on discontinuation)</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment in patients stratified by age, gender, stage and performance status.</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in patients stratified by age, gender, stage and performance status.</measure>
    <time_frame>6 months</time_frame>
    <description>Retrospective population [2009 to 2013]</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">157</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        hospital clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received gefitinib first line in the UK Single Payment Access (SPA)
             scheme

          -  Locally advanced or metastatic EGFR mutation positive NSCLC

          -  Supplied with first pack of gefitinib prior to 1st January 2012

        Exclusion Criteria:

          -  Patient was treated privately (i.e. outside the NHS)

          -  Gefitinib was second-line therapy following treatment failure on a prior therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiona Blackhall, MBCHB FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Nhs Trust</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital Nhs Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals Nhs Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York District Hospital</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>epidermal growth factor receptor mutation</keyword>
  <keyword>gefitinib</keyword>
  <keyword>Iressa</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

